Volume 120, Issue 5 , Pages 1103-1109, November 2007
The effect of corticosteroids on the disposal of long-acting β2-agonists by airway smooth muscle cells
Background
Organic cation transporters (OCTs) have an important role in tissue distribution and elimination of cationic drugs. Carrier-mediated disposal of cationic bronchodilators in the airway tissue, however, is incompletely understood.
Objectives
We sought to assess the uptake of long-acting β2-agonist bronchodilators by bronchial and vascular smooth muscle cells.
Methods
Human airway cells and tissues obtained from organ donors were evaluated for cationic drug transporter expression by means of quantitative RT-PCR and immunofluorescence. For in vitro functional studies, tritiated formoterol and tritiated salmeterol uptake by bronchial and vascular smooth muscle cells was measured.
Results
Quantitative RT-PCR analysis revealed high mRNA levels for the corticosteroid-sensitive OCT3 in bronchial and vascular smooth muscle cells. Immunofluorescence staining of airway sections confirmed OCT3 expression in these cells. In bronchial smooth muscle cells, uptake of the cationic formoterol was inhibited with OCT inhibitors. Corticosteroids also inhibited formoterol uptake through a rapid (within 15 minutes) nongenomic action, with the following rank order for inhibitory potency: corticosterone > budesonide > fluticasone. The corticosteroid-induced inhibition was significantly higher in vascular than bronchial smooth muscle cells. In comparison with formoterol, uptake of the noncharged lipophilic salmeterol was approximately 10-fold higher and insensitive to all OCT inhibitors and corticosteroids.
Conclusions
Our findings suggest that corticosteroids, through OCT3 inhibition, rapidly interfere with the disposal of cationic drugs by smooth muscle cells in the airway.
Clinical implications
This novel immediate interaction between corticosteroids and cationic β2-agonist bronchodilators supports the use of such combinations in the pharmacotherapy of asthma.
Key words: Bronchial smooth muscle, organic cation transporter, corticosteroids, budesonide, fluticasone, nongenomic, long-acting β2-agonists, formoterol, salmeterol
Abbreviations used: DEC22, 1,1′-Diethyl-2,2′-cyanine, IC50, Inhibitory concentration of 50%, MPP+, N-methyl-4-phenylpyridinium, OCT, Organic cation transporter, OCTN, Organic cation/carnitine transporter, TEA+, Tetraethylammonium
Supported in part by an academic research grant from AstraZeneca and National Heart, Lung, and Blood Institute grants HL-60644 and HL-66125. G.H. is a recipient of the Bolyai Fellowship of the Hungarian Academy of Sciences.
Disclosure of potential conflict of interest: A. Wanner has received grant support from AstraZeneca. The other authors have declared that they have no conflict of interest.
PII: S0091-6749(07)01629-6
doi:10.1016/j.jaci.2007.08.034
© 2007 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Volume 120, Issue 5 , Pages 1103-1109, November 2007
